Market Cap 1.52M
Revenue (ttm) 0.00
Net Income (ttm) -9.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,705,700
Avg Vol 6,835,680
Day's Range N/A - N/A
Shares Out 4.87M
Stochastic %K 2%
Beta 0.82
Analysts Strong Buy
Price Target $12.00

Company Profile

ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company that develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100,...

Industry: Biotechnology
Sector: Healthcare
Phone: 754 231 1688
Address:
2200 N. Commerce Parkway, Suite 208, Weston, United States
WallStVisions
WallStVisions Oct. 3 at 1:06 PM
GIPR is the kind of play that only makes sense before it takes off. Real estate backed. Undervalued. And now with serious whispers of a crypto treasury strategy that could turn this into the next multi-sector rocket. 20x–50x isn’t hype it’s math if they execute. $ZVSA $IMUX $GENE $BTTX $ACXP
0 · Reply
Q12021Dreaming
Q12021Dreaming Oct. 3 at 11:40 AM
$ZVSA up 10% I'll take it 💲🐂💲
0 · Reply
Earth4thewin
Earth4thewin Sep. 30 at 6:23 PM
$ZVSA it seems someone is being sneaky trying to accumulate shares without driving the bids up 😅
0 · Reply
Stmkr
Stmkr Sep. 25 at 2:17 PM
$ZVSA FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis in Jul 2025. So 12w proteinuria data possibly Oct 2025. could be a very nuce catalyst here at current valuation
1 · Reply
Earth4thewin
Earth4thewin Sep. 24 at 2:01 AM
$ZVSA Is there A hail Mary chance in hell this company manages to pull a rabbit out of A hat and save this sinking ship ?🤔 https://phys.org/news/2025-09-lipids-play-key-role-immune.html
0 · Reply
thefly2
thefly2 Sep. 23 at 7:55 PM
$ZVSA is the current OS shares really 8mil.?
0 · Reply
Earth4thewin
Earth4thewin Sep. 22 at 4:01 PM
0 · Reply
Devoted2Execution
Devoted2Execution Sep. 19 at 4:04 AM
VRME has everything lining up: ✔️ Cash flow positive ✔️ Golden cross forming ✔️ UPS deal in place ✔️ Tight float The chart is setting up for a textbook breakout and nobody’s paying attention yet. $ZVSA $NBY $AKAN $PALI $GENE
0 · Reply
Earth4thewin
Earth4thewin Sep. 16 at 4:44 PM
$ZVSA How long would it take to hear if the drug proved to be effective with this patient?
2 · Reply
kancunbum
kancunbum Sep. 15 at 5:48 AM
$ZVSA get your early seat now. Its going to errupt.
2 · Reply
Latest News on ZVSA
No data available.
WallStVisions
WallStVisions Oct. 3 at 1:06 PM
GIPR is the kind of play that only makes sense before it takes off. Real estate backed. Undervalued. And now with serious whispers of a crypto treasury strategy that could turn this into the next multi-sector rocket. 20x–50x isn’t hype it’s math if they execute. $ZVSA $IMUX $GENE $BTTX $ACXP
0 · Reply
Q12021Dreaming
Q12021Dreaming Oct. 3 at 11:40 AM
$ZVSA up 10% I'll take it 💲🐂💲
0 · Reply
Earth4thewin
Earth4thewin Sep. 30 at 6:23 PM
$ZVSA it seems someone is being sneaky trying to accumulate shares without driving the bids up 😅
0 · Reply
Stmkr
Stmkr Sep. 25 at 2:17 PM
$ZVSA FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis in Jul 2025. So 12w proteinuria data possibly Oct 2025. could be a very nuce catalyst here at current valuation
1 · Reply
Earth4thewin
Earth4thewin Sep. 24 at 2:01 AM
$ZVSA Is there A hail Mary chance in hell this company manages to pull a rabbit out of A hat and save this sinking ship ?🤔 https://phys.org/news/2025-09-lipids-play-key-role-immune.html
0 · Reply
thefly2
thefly2 Sep. 23 at 7:55 PM
$ZVSA is the current OS shares really 8mil.?
0 · Reply
Earth4thewin
Earth4thewin Sep. 22 at 4:01 PM
0 · Reply
Devoted2Execution
Devoted2Execution Sep. 19 at 4:04 AM
VRME has everything lining up: ✔️ Cash flow positive ✔️ Golden cross forming ✔️ UPS deal in place ✔️ Tight float The chart is setting up for a textbook breakout and nobody’s paying attention yet. $ZVSA $NBY $AKAN $PALI $GENE
0 · Reply
Earth4thewin
Earth4thewin Sep. 16 at 4:44 PM
$ZVSA How long would it take to hear if the drug proved to be effective with this patient?
2 · Reply
kancunbum
kancunbum Sep. 15 at 5:48 AM
$ZVSA get your early seat now. Its going to errupt.
2 · Reply
WallStVisions
WallStVisions Sep. 12 at 10:49 PM
The MITQ setup is almost unfair. Golden cross coming, micro float primed, no dilution, no hype… yet. You don’t wait for volume—you get in before it shows up. $VERB $ZVSA $OPAD $FEMY $THMO
0 · Reply
Pipelinepivots
Pipelinepivots Sep. 12 at 7:47 AM
The float on MITQ is so small it can’t take pressure. Now layer in a golden cross and breakout volume starting to perk. Most traders will notice it AFTER it gaps. I’m not waiting for headlines. $SYTA $AGRI $ZVSA $NBY
0 · Reply
sumset1965
sumset1965 Sep. 11 at 3:58 AM
$ZVSA When this blows, everyone will be Blindsided.
1 · Reply
Quantumup
Quantumup Sep. 10 at 3:13 PM
H.C. Wainwright reiterated $TVTX Buy/$47: We see adapted REMS as competitive advantage. We view this as positive news for Travere, particularly as it competes with Novartis' ( $NVO; not rated) Vanrafia (atrasentan), which received accelerated approval in IgAN in April 2025 without a REMS. FILSPARI now also carries a reduced REMS, removing a logistical burden for both patients and prescribers. In our view, this change provides FILSPARI with a competitive advantage in a chronic condition like IgAN, where ease of use, adherence, and long-term safety are key considerations. Recall that FILSPARI launched in the U.S. in 1Q23, benefiting from early entry and increasing physician familiarity. Travere has executed well commercially despite the previous REMS requirements, and with these removed, we expect prescriber willingness to adopt FILSPARI to increase further. $ZVSA $NVS
0 · Reply
Quantumup
Quantumup Sep. 10 at 2:47 PM
Jefferies reiterated $TVTX Buy/$35. $ZVSA $NVS Jefferies in its note said: We believe the AdCom cancellation for FSGS is a clear positive for $TVTX and fits in w/ our bull-case scenario -- suggests that FDA is fully on board w/ using UPCR as FSGS 1° endpt for full approval. We caught up w/ mgmt, and they remain confident in getting Filsapri approved for FSGS. PDUFA date 1/13/26 remains the same, but we think approval could come in earlier. Reiterate our PT $35 heading into the likely approval.
0 · Reply
Honning
Honning Sep. 10 at 2:26 PM
$ZVSA https://finance.yahoo.com/news/zyversa-therapeutics-highlights-data-reinforcing-115500436.html
0 · Reply
kancunbum
kancunbum Sep. 9 at 10:54 PM
$ZVSA news from 3 days ago https://finance.yahoo.com/news/zyversa-therapeutics-highlights-lipidomic-data-115500827.html
0 · Reply
kancunbum
kancunbum Sep. 9 at 10:53 PM
$ZVSA NEWS https://www.tipranks.com/news/the-fly/zyversa-therapeutics-reports-q2-eps-46c-vs-3-31-last-year-thefly
0 · Reply
prismmarketview
prismmarketview Sep. 3 at 4:30 PM
PRISM Mid-Day Movers Shattuck Labs, Inc. ( $STTK) up +26.24% after OrbiMed invests $5.47M, boosting confidence in its immunotherapy pipeline. Biotricity Inc. ( $BTCY) up +23.31% following an announcement of its expansion into cardiac monitoring for consumer wearables with FDA-cleared tech. Other PRISM Mid-Day Movers: ZyVersa Therapeutics , Inc. ( $ZVSA) up 14.81% Aethlon Medical, Inc. ( $AEMD) down 15.21% https://prismmarketview.com/prism-mid-day-movers-share-purchases-and-wearables-innovation-drive-index-gains/
0 · Reply
Arya3t
Arya3t Aug. 31 at 12:55 AM
1 · Reply
Arya3t
Arya3t Aug. 30 at 2:38 PM
0 · Reply
ali9989
ali9989 Aug. 28 at 1:52 PM
$ZVSA any genuine update for this bs stock? We everr gonna see .50
0 · Reply